Lidocaine’s Impact on Tinnitus Symptoms

Approximately 15% of the global population experiences tinnitus, a persistent ringing or buzzing in the ears with no external source. A new systematic review and meta-analysis has evaluated the potential of a well-known local anesthetic, lidocaine, to alleviate this common symptom. The study, led by Anas Alashram and published in the *Egyptian Journal of Otolaryngology*, consolidates evidence from 12 randomized controlled trials involving 550 participants to assess lidocaine’s efficacy.

How Researchers Evaluated the Evidence

The team conducted a comprehensive search of major scientific databases, including PubMed, MEDLINE, and The Cochrane Library, for studies published up to November 2025. They focused exclusively on randomized controlled trials, the gold standard for clinical evidence, where lidocaine was administered to treat tinnitus. To ensure the reliability of their conclusions, the authors used the Cochrane Risk of Bias 2 (RoB 2) tool to critically appraise each included study. This process identified four studies as having a low risk of bias, while the remaining eight had some concerns, often related to how participants were assigned to treatment groups or how outcomes were measured.

Lidocaine’s Effect on Tinnitus Severity: A Null Result

The core finding from the pooled data is clear. Lidocaine did not produce a statistically significant reduction in standardized measures of tinnitus severity. The meta-analysis showed a mean effect size of 0.358 on the Tinnitus Handicap Inventory (THI), with a confidence interval crossing zero (95% CI: -0.092 to 0.809). Similarly, the effect on Visual Analog Scale (VAS) ratings for tinnitus intensity was 0.145 (95% CI: -0.398 to 0.687). The high statistical heterogeneity (I² = 77-79%) indicates substantial variation in results across the different studies, making a single, definitive conclusion difficult.

Signals of Potential Benefit in Specific Symptoms

Despite the non-significant primary result, the review notes signals of potential effect in other outcomes. Several individual studies suggested that both intravenous and intratympanic (injected into the middle ear) lidocaine might lead to temporary reductions in tinnitus pitch, subjective loudness, and associated distress. Some data also pointed to possible improvements in hearing thresholds. These findings hint that lidocaine, as a sodium channel blocker, may temporarily reduce abnormal neural excitability in the auditory pathway. This mechanism is conceptually related to other neuromodulation approaches for tinnitus that aim to calm overactive brain networks.

Practical Implications and Future Directions

For patients and clinicians, this review suggests caution. Lidocaine is not a proven, reliable treatment for reducing the overall severity of tinnitus. The temporary and variable effects on pitch or loudness reported in some studies do not constitute a robust treatment strategy. The significant variation in how the drug was administered—a major source of the heterogeneity—means there is no established optimal protocol. This mirrors challenges seen in other areas, such as the varied approaches in treating sudden hearing loss, where treatment protocols can differ widely.

The authors state that future research must address these inconsistencies. Well-designed trials with standardized lidocaine protocols, clearly defined patient subgroups, and longer-term follow-up are needed to determine if any subset of people with tinnitus could benefit. The inconclusive nature of this pharmacological approach reinforces the importance of comprehensive management strategies. These often include sound therapy and counseling, which can help manage the distress associated with tinnitus, a challenge also faced by those with conditions like misophonia. Furthermore, as tinnitus often disrupts sleep, patients may benefit from reviewing general evidence-based sleep hygiene practices to improve rest.

A Cautious Conclusion on an Old Hypothesis

The idea of using lidocaine for tinnitus is not new, but this systematic review provides the most current synthesis of controlled trial data. The conclusion is that the evidence remains inconclusive. While the drug may briefly alter the sensory characteristics of tinnitus for some individuals, it does not demonstrate a consistent, significant effect on the condition’s overall burden. This work, published under DOI 10.1186/s43163-026-01130-3, effectively narrows the focus for future research, emphasizing the need for precision in how potential treatments are tested for this complex symptom.